Prodexa T contains a synthetic glucocorticoid (hormone of the adrenal glands) with effects on metabolism, electrolyte balance and tissue function.
Prodexa T is indicated in diseases which require a systemic treatment with glucocorticoids. These include, depending on the appearance and severity:
• cerebral edema caused by brain tumor, neurosurgical intervention, brain abscess, bacterial meningitis;
• severe acute asthma attack;
• initial treatment of extensive, severe, acute skin diseases, such as erythroderma, pemphigus vulgaris, acute eczema;
• treatment of rheumatic systemic diseases (rheumatic diseases, which can affect the internal organs) such as systemic lupus erythematosus;
• active rheumatoid arthritis with severe progressive course form, e.g. fast destructively remitting forms and / or with extra-articular manifestations;
• serious infections with toxic conditions (e.g. tuberculosis, typhus; only concomitantly with anti-infective therapy);
• palliative treatment of malignant tumors;
• prophylaxis and treatment of vomiting caused by cytostatic treatment;
• prophylaxis and treatment of post-operative vomiting;
• hormone replacement therapy: at reduced or absent adrenal function (adrenogenital syndrome) in adults.